Elke Bromberg

Dr. Elke Bromberg

Laboratory of Biology and Development of the Nervous System, Escola de Ciências da Saúde e da Vida, Pontifícia Universidade Católica do Rio Grande do Sul, Porto Alegr, Brazil

Research Focus & Metrics

Academic Career Length

32Years (1995-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 August 2018 in Molecular Neurobiology
Verified
Journal Article
Open access
PDF file
BGBruno Lima Giacobbo
Bruno Lima Giacobbo
JDJanine Doorduin
Janine Doorduin
HKHans Klein
Hans Klein
RDRudi A. J. O. Dierckx
Rudi A. J. O. Dierckx
EBElke Bromberg
Elke Bromberg
Erik de VriesErik de Vries
Erik de Vries
Brain-derived neurotrophic factor (BDNF) is one of the most studied neurotrophins in the healthy and diseased brain. As a result, there is a large body of evidence that associates BDNF with neuronal maintenance, neuronal survival, plasticity, and neurotransmitter regulation. Patients with psychiatric and neurodegenerative disorders often have reduced BDNF concentrations in their blood and brain. A current hypothesis suggests that these abnormal BDNF levels might be due to the chronic inflammatory state of the brain in certain disorders, as neuroinflammation is known to affect several BDNF-related signaling pathways. Activation of glia cells can induce an increase in the levels of pro- and antiinflammatory cytokines and reactive oxygen species, which can lead to the modulation of neuronal function and neurotoxicity observed in several brain pathologies. Understanding how neuroinflammation is involved in disorders of the brain, especially in the disease onset and progression, can be crucial for the development of new strategies of treatment. Despite the increasing evidence for the involvement of BDNF and neuroinflammation in brain disorders, there is scarce evidence that addresses the interaction between the neurotrophin and neuroinflammation in psychiatric and neurodegenerative diseases. This review focuses on the effect of acute and chronic inflammation on BDNF levels in the most common psychiatric and neurodegenerative disorders and aims to shed some light on the possible biological mechanisms that may influence this effect. In addition, this review will address the effect of behavior and pharmacological interventions on BDNF levels in these disorders.

24 June 1997 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
PDF file
RBRamon Bernabeu
Ramon Bernabeu
LBLia Bevilaqua
Lia Bevilaqua
PAPatricia Ardenghi
Patricia Ardenghi
EBElke Bromberg
Elke Bromberg
PSPaulo Schmitz
Paulo Schmitz
JMJorge H. Medina
Jorge H. Medina
CAMP/cAMP-dependent protein kinase (PKA) signaling pathway has been recently proposed to participate in both the late phase of long term potentiation in the hippocampus and in the late, protein synthesis-dependent phase of memory formation. Here we report that a late memory consolidation phase of an inhibitory avoidance learning is regulated by an hippocampal cAMP signaling pathway that is activated, at least in part, by D 1 /D 5 receptors. Bilateral infusion of SKF 38393 (7.5 μg/side), a D 1 /D 5 receptor agonist, into the CA 1 region of the dorsal hippocampus, enhanced retention of a step-down inhibitory avoidance when given 3 or 6 h, but not immediately (0 h) or 9 h, after training. In contrast, full retrograde amnesia was obtained when SCH 23390 (0.5 μg/side), a D 1 /D 5 receptor antagonist, was infused into the hippocampus 3 or 6 h after training. Intrahippocampal infusion of 8Br-cAMP (1.25 μg/side), or forskolin (0.5 μg/side), an activator of adenylyl cyclase, enhanced memory when given 3 or 6 h after training. KT5720 (0.5 μg/side), a specific inhibitor of PKA, hindered memory consolidation when given immediately or 3 or 6 h posttraining. Rats submitted to the avoidance task showed learning-specific increases in hippocampal 3 H-SCH 23390 binding and in the endogenous levels of cAMP 3 and 6 h after training. In addition, PKA activity and P-CREB (phosphorylated form of cAMP responsive element binding protein) immunoreactivity increased in the hippocampus immediately and 3 and 6 h after training. Together, these findings suggest that the late phase of memory consolidation of an inhibitory avoidance is modulated cAMP/PKA signaling pathways in the hippocampus.

1 January 2005 in Behavioural Brain Research
Verified
Journal Article
Closed access
MLMaria Noêmia M. de Lima
Maria Noêmia M. de Lima
DLDaniela C. Laranja
Daniela C. Laranja
EBElke Bromberg
Elke Bromberg
Rafael Roesler RoeslerRafael Roesler Roesler
Rafael Roesler Roesler
NSNadja Schröder
Nadja Schröder

1 August 1997 in Behavioural Pharmacology
Verified
Journal Article
Closed access
LBL Bevilaqua
L Bevilaqua
PAP Ardenghi
P Ardenghi
NSNadja Schröder
Nadja Schröder
EBElke Bromberg
Elke Bromberg
PSP K Schmitz
P K Schmitz
III Izquierdo
I Izquierdo
Rats implanted bilaterally with cannulae in the CA1 region of the dorsal hippocampus or in the amygdala were trained in one-trial step-down inhibitory (passive) avoidance using a 0.4 mA footshock. At various times after training (0, 1.5, 3, 6 or 9 h for animals implanted in the hippocampus; 0 or 3 h for those implanted in the amygdala), they received infusions of 8-Br-cAMP (cyclic adenosine monophosphate) (1.25 micrograms/side), SKF38393 (7.5 micrograms/side), SCH23390 (0.5 microgram/side), norepinephrine ClH (0.3 microgram/side), timolol ClH (0.3 microgram/side), 8-HO-DPAT (2.5 micrograms/side), NAN-190 (2.5 micrograms/side), forskolin (0.5 microgram/side) or KT5720 (0.5 microgram/side). Rats were tested for retention 24 h after training. SKF38393 is an agonist and SCH23390 an antagonist at dopamine D1 receptors, timolol is a beta-adrenoceptor antagonist, 8-HO-DPAT is an agonist and NAN-190 an antagonist at 5HT1A receptors, forskolin enhances adenylyl cyclase, and KT5720 inhibits protein kinase A. When given into the hippocampus 0 h post-training, norepinephrine enhanced memory and KT5720 was amnestic. When given 1.5 h after training, all treatments were ineffective. When given 3 or 6 h post-training, 8-Br-cAMP, forskolin, SKF 38393, noradrenaline and NAN-190 caused memory facilitation, and KT5720, SCH23390, timolol and 8-HO-DPAT caused retrograde amnesia. At 9 h from training, all treatments were again ineffective. When given into the amygdala 0 or 3 h post-training all treatments were ineffective, except for noradrenaline at 0 h, which caused retrograde facilitation. The data agree with the suggestion that in the hippocampus, but not the amygdala, a cAMP/protein kinase A pathway is involved in memory consolidation at 3 and 6 h from training, and that this is regulated by D1, beta, and 5HT1A receptors. This correlates with a previous report of increased cAMP levels, protein kinase A activity and P-CREB levels at 3-6 h from training in rat hippocampus in this task. This may be taken to suggest that the hippocampus, but not the amygdala, is involved in the long-term storage of step-down inhibitory avoidance in the rat.

29 September 2012 in Journal of Neurology
Verified
Journal Article
Closed access
PDF file
LWLucia Bartmann Wild
Lucia Bartmann Wild
DLDaiane Borba Lima
Daiane Borba Lima
JBJoana Bisol Balardin
Joana Bisol Balardin
LRLuana Rizzi
Luana Rizzi
BGBruno Lima Giacobbo
Bruno Lima Giacobbo
EBElke Bromberg
Elke Bromberg

1 August 2004 in Pharmacology Biochemistry and Behavior
Verified
Journal Article
Closed access
MPManuela Polydoro
Manuela Polydoro
NSNadja Schröder
Nadja Schröder
MLMaria Noemia M. Lima
Maria Noemia M. Lima
FCFábio Caldana
Fábio Caldana
DLDaniela C. Laranja
Daniela C. Laranja
FDFelipe Dal-Pizzol
Felipe Dal-Pizzol